Microba Life Sciences Limited (MAP.AX)
AUD 0.19
(0.0%)
AUD 0.19
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 | - AUD | 0.0% |
| 2023 | 234.06 Thousand AUD | -51.62% |
| 2022 | 483.76 Thousand AUD | 624.6% |
| 2021 | 66.76 Thousand AUD | -72.8% |
| 2020 | 245.42 Thousand AUD | -11.47% |
| 2019 | 277.21 Thousand AUD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 510.62 Thousand AUD | 0.0% |
| 2024 Q4 | - AUD | 0.0% |
| 2024 Q2 | 510.62 Thousand AUD | 0.0% |
| 2024 FY | - AUD | -100.0% |
| 2023 Q3 | 234.06 Thousand AUD | -49.67% |
| 2023 FY | 234.06 Thousand AUD | -51.62% |
| 2023 Q4 | 483.76 Thousand AUD | 106.68% |
| 2023 Q2 | 465.07 Thousand AUD | 0.0% |
| 2023 Q1 | 465.07 Thousand AUD | -3.86% |
| 2022 FY | 483.76 Thousand AUD | 624.6% |
| 2022 Q4 | 483.76 Thousand AUD | 0.0% |
| 2022 Q3 | 483.76 Thousand AUD | -27.75% |
| 2022 Q2 | 669.57 Thousand AUD | 0.0% |
| 2022 Q1 | 669.57 Thousand AUD | 902.92% |
| 2021 Q3 | 66.76 Thousand AUD | 0.0% |
| 2021 FY | 66.76 Thousand AUD | -72.8% |
| 2021 Q1 | - AUD | 0.0% |
| 2021 Q4 | 66.76 Thousand AUD | 0.0% |
| 2020 FY | 245.42 Thousand AUD | -11.47% |
| 2019 FY | 277.21 Thousand AUD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Australian Clinical Labs Limited | 55.06 Million AUD | 100.0% |
| BCAL Diagnostics Limited | 400.22 Thousand AUD | 100.0% |
| Genetic Signatures Limited | - AUD | NaN% |
| Genetic Technologies Limited | - AUD | NaN% |
| Healius Limited | 420.8 Million AUD | 100.0% |
| Imagion Biosystems Limited | 750 Thousand AUD | 100.0% |
| Integral Diagnostics Limited | 219.75 Million AUD | 100.0% |
| INOVIQ Ltd | - AUD | NaN% |
| Monash IVF Group Limited | 59.56 Million AUD | 100.0% |
| Rhythm Biosciences Limited | - AUD | NaN% |
| Sonic Healthcare Limited | 2.69 Billion AUD | 100.0% |